Do open label blinded outcome studies of novel anticoagulants versus warfarin have equivalent validity to those carried out under double-blind conditions?

Thrombosis and Haemostasis

Volumn 109, Issue 3, 2013, Pages 497-503

  O'Neil, William M ^a   Welner, Sharon A ^a   Lip, Gregory Y H ^b  

^a LA SER Analytics   (Canada)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Clinical studies; Coagulation inhibitors; Management of disease; Metaanalysis; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; IDRAPARINUX; RIVAROXABAN; WARFARIN; XIMELAGATRAN;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HEART INFARCTION; HUMAN; ISCHEMIA; MORTALITY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOLOGY; CLINICAL TRIALS, PHASE III AS TOPIC; DOUBLE-BLIND METHOD; HUMANS; MYOCARDIAL INFARCTION; ODDS RATIO; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; STROKE; TREATMENT OUTCOME; VITAMIN K; WARFARIN;

EID: 84874760694     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-10-0715     Document Type: Article

References (25)

1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
2. Gallagher AM, Setakis E, Plumb JM, et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011; 106: 968-977.
3. Ogilvie IM, Welner SA, Cowell W, et al. Ischaemic stroke and bleeding rates in 'real-world' atrial fibrillation patients. Thromb Haemost 2011; 106: 34-44.
4. Wilke T, Groth A, Mueller S, et al. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost 2012; 107: 1053-1065.
5. Ahrens I, Lip GY, Peter K. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation? Thromb Haemost 2011; 105: 574-578.
6. Casteels M, Flamion B. Open-label trials and drug registration: a European regulator's view. J Thromb Haemost 2008; 6: 232-234.
7. Sever PS, Dahlof B, Poulter NR, et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens 2001; 19: 1139-1147.
8. Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded endpoint (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press 1992; 1: 113-119.
9. Smith DH, Neutel JM, Lacourciere Y, et al. Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as doubleblind, placebo-controlled trials with respect to ABPM measurements. J Hypertens 2003; 21: 1291-1298.
10. Buller HR, Halperin JL, Bounameaux H, et al. Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants. J Thromb Haemost 2008; 6: 227-229.
11. Cochrane IMS. Review Manager (RevMan) version 5.1. Available at: http: //ims.cochrane.org/revman. Accessed: December 16, 2011.
12. Eikelboom JW, O'Donnell M, Yusuf S, et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 2010; 159: 348-353.
13. Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009; 157: 805-810.
14. Bousser MG, Bouthier J, Buller HR, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008; 371: 315-321.
15. Halperin JL. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003; 146: 431-438.
16. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
17. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363: 1875-1876.
18. Olsson SB, Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 1691-1698.
19. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010; 159: 340-347.
20. Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010; 159: 331-339.
21. Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. J Am Med Assoc 2005; 293: 690-698.
22. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
23. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
24. Mahaffey KW, Fox KAA. Rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Available at: http: //my.americanheart.org/idc/ groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ ucm_426788.pdf. Accessed February 17, 2012.
25. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.